PHOENIX supports its customers to overcome difficulties bridging the “innovation valley of death”, enabling transfer of nanopharmaceuticals from lab bench to clinical trials.
As the Single Entry Point (SEP) of the PHOENIX SEP brings together a network of facilities, technologies, services and expertise from the members of the PHOENIX Open Innovation Test Bed (OITB) for all the R&D/I and technology transfer aspects from characterization, testing, verification up to scale-up, GMP manufacturing and regulatory guidance in a timely and cost-friendly manner.
In September, linked to the European Consortium for Continuous Pharmaceutical Manufacturing (ECCPM) 2024 Forum in Graz, Austria, we will introduce PHOENIX and its services in an online event.
You’ll learn about the PHOENIX services in the following areas:
Physico-Chemical Characterisation
In vitro Characterisation
In vivo Characterisation
Manufacturing
Innovation (including regulatory aspects)
